Posts tagged “Pozen”
While Pozen works on landing a drug partner to market its prospective new heart drug, it's now starting to look like Pozen might need global partners. Read more about the company's status.
AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?
Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?
The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?
Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.
The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.
The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.
- GSK shares climb 3% after better-than-expected earnings
- Quintiles beats Street expectations despite impact of stronger dollar
- The 'your phone'? Motorola offers personal choices with new phones
- Fed is likely to delay 1st rate hike in 9 years a bit longer
- Triangle newborn health screening firm nabs $13M